Stocks Health care UPB
NASDAQ · Health careUpstream Bio, Inc. (UPB)
Upstream Bio, Inc. brought in $3.2M of revenue over the twelve months to June 30, 2026, up 16.0% from a year earlier. It posted a net loss of $156.5M. In fiscal 2025 capital spending exceeded operating cash flow by $133.4M. At June 30, 2026 it held $79.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Upstream Bio, Inc.
- Net worth
- Upstream Bio, Inc. has a market value (market cap) of $196.1M at the latest share price, and shareholders' equity of $271M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.9M (+20.4% year on year), with a net loss of $143.4M. Over the 12 months to June 30, 2026: revenue $3.2M, net loss $156.5M.
- Cash flow
- In fiscal 2025 operations used $133.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Upstream Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Upstream Bio, Inc. does
Upstream Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker UPB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.9M | -$143.4M | -$2.66 | -$133.4M |
| 2024 | $2.4M | -$62.8M | -$5.58 | -$59.7M |
| 2024 | $2.4M | -$20.5M | -$12.95 | -$38.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where UPB ranks in Health care
Latest SEC filings
What Upstream Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- October 29, 2026Passive stake changed SCHEDULE 13G/A
- September 1, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 18% to $773K versus the same quarter last year; diluted EPS -$0.73 versus -$0.74.
- August 11, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 10, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 83% to $1M versus the same quarter last year; diluted EPS -$0.75 versus -$0.51.
Insider trades
What the people running Upstream Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $27.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 16, 2026 | Ambrose AllisonGeneral Counsel | Sold | 485 | $2.7K |
| September 16, 2026 | Gray MichaelCFO and COO | Sold | 853 | $4.7K |
| September 16, 2026 | Houghton AdamChief Business Officer | Sold | 700 | $3.8K |
| September 16, 2026 | Sutherland Everett RandChief Executive Officer, Director | Sold | 2,095 | $11.5K |
| September 16, 2026 | Deykin AaronChief Medical Officer | Sold | 895 | $4.9K |
| June 16, 2026 | Ambrose AllisonGeneral Counsel | Sold | 477 | $2.9K |
| June 16, 2026 | Deykin AaronChief Medical Officer | Sold | 895 | $5.5K |
| June 16, 2026 | Houghton AdamChief Business Officer | Sold | 700 | $4.3K |
Who owns UPB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 14.8% | August 6, 2025 |
| Norges Bank13G, passive | 7.73% | August 12, 2026 |
| Decheng Capital Global Life Sciences Fund IV, L.P.13G, passive with 4 related filers | 5% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 149 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 8,162,897 | +61,334 |
| Orbimed Advisors LLC | 5,693,589 | 0 |
| Norges Bank | 3,768,619 | new |
| BlackRock, Inc. | 3,753,358 | +382,669 |
| Decheng Capital LLC | 2,724,868 | 0 |
| Enavate Sciences GP, LLC | 2,459,703 | 0 |
| Vanguard Capital Management LLC | 1,876,734 | +3,160 |
| Millennium Management LLC | 1,143,775 | +206,452 |
| D. E. Shaw & Co., Inc. | 1,036,044 | +215,564 |
| Jpmorgan Chase & Co | 1,012,044 | +549,043 |
| Qube Research & Technologies Ltd | 978,500 | +359,179 |
| Parkman Healthcare Partners LLC | 935,247 | +148,464 |
| Geode Capital Management, LLC | 931,261 | -19,356 |
| SEB Asset Management AB | 878,473 | 0 |
| Woodline Partners LP | 831,481 | 0 |
| State Street Corp | 766,323 | +60,973 |
| Vanguard Portfolio Management LLC | 712,667 | -15,044 |
| Y-Intercept (Hong Kong) Ltd | 693,555 | -307,076 |
| Bain Capital Life Sciences Investors, LLC | 600,949 | -266,262 |
| Aqr Capital Management LLC | 544,869 | +472,698 |
Insiders
5 insiders reported holding 167,425 shares in total, about $599.4K at the last price.
| Holder | Shares |
|---|---|
| Sutherland Everett RandChief Executive Officer, Director | 68,717 |
| Deykin AaronChief Medical Officer | 32,302 |
| Gray MichaelCFO and COO | 27,942 |
| Houghton AdamChief Business Officer | 22,901 |
| Ambrose AllisonGeneral Counsel | 15,563 |
Questions about UPB
What does Upstream Bio, Inc. do?
Upstream Bio, Inc. is a company in the Health care sector, listed on NASDAQ as UPB. Its shares trade on NASDAQ under the ticker UPB.
What is Upstream Bio, Inc.'s net worth?
Upstream Bio, Inc. has a market value (market cap) of $196.1M at the latest share price, and shareholders' equity of $271M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Upstream Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $156.5M on revenue of $3.2M.
How much revenue does Upstream Bio, Inc. make?
Over the twelve months to June 30, 2026 Upstream Bio, Inc. reported revenue of $3.2M. That is 16.0% more than a year earlier.
When did Upstream Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Upstream Bio, Inc.'s next earnings report?
Upstream Bio, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare UPB with
Follow UPB
Get an email when Upstream Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Upstream Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.